Abiraterone Acetate in Molecular Apocrine Breast Cancer (AMA)

A Phase II Trial Evaluating the Activity of Abiraterone Acetate Plus Prednisone in Patients With a Molecular Apocrine HER2-negative Locally Advanced or Metastatic Breast Cancer

The purpose of this study is to estimate antitumour activity of abiraterone acetate in Patients with a Molecular Apocrine HER2-negative locally advanced or metastatic Breast Cancer.

Study Overview

• Status: Completed
• Conditions: Breast Cancer
• Intervention / Treatment: Drug: Abiraterone Acetate

Detailed Description

Screening : All women 18+, with a confirmed locally advanced or metastatic Triple Negative Breast Cancer (TNBC), will be screened and invited to participate (300-500 patients).

Only patients with a centralized confirmation of ER-/PR-/HER2- and evaluation of AR+ will be included and treated with abiraterone acetate plus prednisone (31 patients).

The Treatment phase comprises a series of 4 weeks-cycles with continuous study treatment. Study drug treatment will continue until the earliest of the following events: disease progression, unacceptable toxicity, or death.

At disease progression, patients must be discontinued from study drug and should be evaluated within 30 days during the Post treatment visit and then entered into the Follow-Up phase.Patients should enter the Follow-Up Period regardless of reason for study drug discontinuation and should be monitored every 3 months (± 7 days) during 2 years.

• Study Type: Interventional
• Enrollment (Actual): 34
• Phase: Phase 2

Contacts and Locations

Study Locations

• France
  • Angers, France
    • ICO - Site Paul Papin
  • Avignon, France
    • Institut Sainte Catherine
  • Besancon, France
    • Chu - Hôpital Jean Minjoz
  • Bordeaux, France
    • Institut Bergonié
  • Bordeaux, France
    • Polyclinique Bordeaux Nord Aquitaine
  • Brest, France
    • Chu de Brest - Hôpital Morvan
  • Caen, France
    • Centre Francois Baclesse
  • Clermont-ferrand, France
    • Centre Jean Perrin
  • Contamine - Sur - Arve, France
    • CH Alpes Léman
  • Dijon, France
    • Centre Georges-François Leclerc
  • Grenoble, France
    • CHU de Grenoble - Hopital Michallon
  • Hyeres, France
    • Clinique Sainte Marguerite
  • La Roche-sur-yon, France
    • CHD de Vendée
  • Lille, France
    • Centre Oscar Lambret
  • Lyon, France
    • Centre Léon Berard
  • Marseille, France
    • Institut Paoli Calmettes
  • Mont de Marsan, France
    • CH de Mont de Marsan
  • Nice, France
    • Centre Antoine Lacassagne
  • Orleans, France
    • Chr D Orleans - Hopital La Source
  • Paris, France
    • Hôpital Saint-Louis
  • Paris, France
    • Hopital Tenon
  • Paris, France
    • Institut Curie - Hopital Claudius Régaud
  • Perpignan, France
    • CH de Perpignan
  • Pierre Benite, France
    • CH Lyon sud
  • Pringy, France
    • CH de la Region d'Annecy
  • Reims, France
    • Institut Jean Godinot
  • Rouen, France
    • Centre Henri Becquerel
  • Saint-cloud, France
    • Institut Curie - Hôpital René Huguenin
  • Saint-herblain, France
    • ICO- Site René Gauducheau
  • Strasbourg, France
    • Centre Paul Strauss
  • Strasbourg, France
    • Hôpital Civil - Strasbourg
  • Thonon Les Bains, France
    • Hôpitaux du Léman
  • Toulouse, France
    • Institut Claudius Regaud
  • Vannes, France
    • CH Bretagne Atlantique
  • Vannes, France
    • Hôpital Privé Océane
  • Villejuif, France
    • Gustave Roussy Cancer Campus

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Women aged ≥18 years;
• Histologically confirmed locally advanced or metastatic breast cancer;
• Triple negative breast cancer:

Estrogen receptor (ER)-negative and Progesterone receptor (PR)-negative, as defined by a <10 % tumour stained cells by immunohistochemistry (IHC); HER2 negative status (i.e. IHC score 0 or 1+, or IHC score 2+ and FISH/SISH/CISH negative), confirmed centrally before inclusion with FFPE tissue from either primary or metastatic breast cancer site*;

• Androgen receptor (AR)-positive, as defined centrally by a ≥10% tumour stained cells by IHC (AR assessment by local pathologist before inclusion is not mandatory);
• Patients could be chemotherapy naïve (provided they are not presenting with life-threatening metastasis) or have received any number of previous lines of chemotherapy (providing their life expectancy is ≥3 months);
• Pre and post menopausal patients are eligible.
• Measurable or non measurable disease according to RECIST v1.1 criteria;
• PS (ECOG) ≤2;
• Normal haematological function: ANC ≥1,500/mm3; platelets count ≥100,000/mm3; haemoglobin >10 g/dl;
• Normal hepatic function: total bilirubin ≤1.5 upper normal limit (UNL); ASAT and ALAT ≤2.5 UNL (≤5 UNL in the presence of liver metastases);
• Creatinine clearance (MDRD formula) ≥50 mL/min OR creatinine ≤1.5 times ULN;
• Normal kalemia (serum potassium ≥3.5 mM), natremia and magnesemia;
• Systolic blood pressure (BP) <160 mm Hg and diastolic BP <95 mm Hg, as documented on inclusion day (Hypertension at baseline assessment allowed provided it is currently controlled under anti-hypertensive drugs);
• Cardiac ejection fraction ≥50% measured by MUGA or ECHO done within 4 weeks before inclusion;
• If receiving a bisphosphonate or denosumab, dose must have been stable for at least 2 doses before inclusion;
• Patient agreeing to use effective contraception during and for ≥ 6 months after completion of study treatment;
• Patient able to comply with the protocol;
• Patient must have signed a written informed consent form prior to any study specific procedures;
• Patient must be affiliated to a Social Health Insurance.

Exclusion Criteria:

• Male breast cancer;
• HER2-positive status (positivity defined as IHC3+ and/or FISH amplification >2.2);
• Other concurrent malignancies, except adequately treated cone-biopsied in situ carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin; patients who have undergone potentially curative therapy for a prior malignancy are eligible provided there is no evidence of disease for ≥ 5 years and patient is deemed to be at low risk for recurrence;
• Active brain metastases or leptomeningeal disease; History of brain metastases allowed provided lesions are stable for at least 3 months as documented by head CT scan or MRI of the brain;
• Non-malignant systemic disease, including active infection or concurrent serious illness that would make the patient a high medical risk;

• Significant cardiovascular disease, including any of the following:

  1. NYHA class III-IV congestive heart failure;
  2. Unstable angina pectoris or myocardial infarction within the past 6 months;
  3. Severe valvular heart disease;
  4. Ventricular arrhythmia requiring treatment.
• Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not be included;
• Patients with known allergies, hypersensitivity or intolerance to abiraterone acetate, prednisone, or their excipients;
• Persistent toxicities ≥ grade 2 from any cause, except chemotherapy-induced alopecia and Grade 2 peripheral neuropathy;
• Active or uncontrolled autoimmune disease requiring concurrent corticosteroid therapy;
• Any gastrointestinal disorder interfering with absorption of the study drug;
• Difficulties with swallowing study capsules;
• Prior anticancer therapy, including radiotherapy, endocrine therapy, immunotherapy, chemotherapy (CT) within the last 3 weeks (2 weeks for oral or weekly CT ; 6 weeks for nitrosoureas and mitomycin C), or other investigational agents ; Concurrent palliative radiotherapy allowed;
• Concurrent enrolment in another clinical trial in which investigational therapies are administered;
• Pregnant women, women who are likely to become pregnant or are breast-feeding;
• Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;
• Patients with history of non compliance to medical regimens or unwilling or unable to comply with the protocol;
• Individual deprived of liberty or placed under the authority of a tutor.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Abiraterone Acetate	Drug: Abiraterone Acetate; Patients will receive abiraterone acetate at 1,000 mg (four 250 mg tablets daily in the morning after an overnight fast) concurrently with prednisone(1) at 10 mg once daily.; Other Names: ZYTIGA

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical benefit rate (CBR)	The 6-months CBR is the measurement of all patients who have a complete response (CR), partial response (PR) or stable disease (SD), according to RECIST criteria v1.1. At six months, patients will be classified as success (Alive at 6 months AND CR/PR/ SD) or failure (dead OR alive with progression).	at 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective response rate (ORR)	The Objective response is defined as complete response (CR) or partial response (PR) according to RECIST criteria v1.1	at 6 months
Duration of overall response (DoR)	The DoR is defined as the time from documentation of tumour response (CR/PR whichever is first recorded) to disease progression, according to RECIST criteria v1.1.	at 6 months
Overall Survival (OS)	The OS is defined as the time from the first administration of abiraterone acetate to death from any cause.	median follow-up = 2 years
Progression-free survival (PFS)	The PFS is defined as the time from the first administration of abiraterone acetate to progression or death of any cause, whichever occurs first.	median follow-up = 2 years
Overall safety profile	The overall safety profile of the treatment is determined by the occurrence of adverse events and toxicities. The severity of the adverse events and toxicities will be graded according the NCI CTCAE scale version 4.0.	during the on-treatment period (defined as the period from the time of first dose of study medications up to 30 days of the last dose)

Collaborators and Investigators

• Sponsor: UNICANCER
• Investigators: Principal Investigator: Hervé BONNEFOI, Prof., Institut Bergonié Bordeaux

Publications and helpful links

General Publications

• Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A, L'Haridon T, Cottu P, Abadie-Lacourtoisie S, You B, Mousseau M, Dauba J, Del Piano F, Desmoulins I, Coussy F, Madranges N, Grenier J, Bidard FC, Proudhon C, MacGrogan G, Orsini C, Pulido M, Goncalves A. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol. 2016 May;27(5):812-8. doi: 10.1093/annonc/mdw067. Epub 2016 Feb 18.

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2013
• Primary Completion (Actual): July 15, 2015
• Study Completion (Actual): July 4, 2018

Study Registration Dates

• First Submitted: April 24, 2013
• First Submitted That Met QC Criteria: April 24, 2013
• First Posted (Estimate): April 29, 2013

Study Record Updates

• Last Update Posted (Actual): February 23, 2021
• Last Update Submitted That Met QC Criteria: February 21, 2021
• Last Verified: February 1, 2021

More Information

Terms related to this study

• Keywords: Breast Cancer; Abiraterone acetate; metastatic; locally advanced; HER2-negative; Molecular Apocrine
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Cytochrome P-450 Enzyme Inhibitors; Hormone Antagonists; Steroid Synthesis Inhibitors; Abiraterone Acetate
• Other Study ID Numbers: CADUSEIME02; 2012-002525-29 (EudraCT Number); UC-0140/1206 (Other Identifier: UNICANCER)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No